FormsNet3 - Blank Form


 

 
Sequence Number:    

 

 
Date Received: __ __ __ __ - __ __- __ __  

 

 
CIBMTR Center Number:    

 

 
CIBMTR Recipient ID:    

 

 
Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __  

HCT type: (check all that apply) 

 

 

gfedcb
Autologous

 

 

gfedcb
Allogeneic, unrelated

 

 

gfedcb
Allogeneic, related

Product type: (check all that apply) 

 

 

gfedcb
Bone marrow

 

 

gfedcb
PBSC

 

 

gfedcb
Single cord blood unit

 

 

gfedcb
Multiple cord blood units

 

 

gfedcb
Other product

 

 
Specify:    

 

 
Is this the report of a second or subsequent transplant for the same disease?

  
 nmlkji

yes  
 nmlkji

no  

 

 
1  What was the date of diagnosis? __ __ __ __ - __ __- __ __  

 

 
2  What was the MDS / MPN subtype?

      

 

 
3  Was the disease (MDS/MPN) therapy related?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
4  Specify prior disease

    
 nmlkji

Breast cancer  

 nmlkji
Hodgkin lymphoma  

 nmlkji
Non-Hodgkin lymphoma 

 nmlkji
Other disease  (malignant or nonmalignant) 

 

 
5  Specify other prior disease:    

 

 
6  Date of diagnosis of prior disease

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
7  Date of diagnosis of prior disease: __ __ __ __ - __ __- __ __  

  Key Fields 

Subsequent Transplant 

  Disease Assessment at Diagnosis Questions: 1 - 18

Form 2014 R3.0: Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Pre-HCT Data  
Center:  CRID: 

           CIBMTR Form 2014 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 1 / 12



 

 
8  Systemic therapy

    (chemotherapy)  

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 

 
9  Radiation

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
10  Other therapy

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
11  Specify other therapy:    

 

 
12  Did the recipient have a predisposing condition?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
13  Specify condition

    
 nmlkji

Aplastic Anemia  Also complete CIBMTR form 2028- APL 

 nmlkji
Bloom syndrome  

 nmlkji
Down syndrome  

 nmlkji
Fanconi anemia  Also complete CIBMTR form 2029- FAN 

 nmlkji
Other condition  

 

 
14  Specify other condition:    

 

 
15  Did the recipient receive any RBC transfusions at the time of diagnosis and/or during the first year post diagnosis?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
16  Were systemic symptoms (B symptoms) present?

    (unexplained fever > 38 C; or night sweats; unexplained weight loss > 10% body weight in six months before diagnosis) 

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 

 
17  Did the recipient have splenomegaly (spleen palpable > 3 cm below left costal margin)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
18  Did the recipient have hepatomegaly (liver edge palpable > 3 cm below right costal margin)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
19  Monocytes

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
20     % 

 

 
21  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
22  Blasts in blood

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
23     % 

 

 
24  Date sample collected: __ __ __ __ - __ __- __ __  

  Laboratory Studies at Diagnosis Questions: 19 - 39

Form 2014 R3.0: Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Pre-HCT Data  
Center:  CRID: 

           CIBMTR Form 2014 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 2 / 12



 

 
25  Was a bone marrow examination performed?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
26  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
27  Cellularity

    
 nmlkji

Decreased  (hypocellular) 

 nmlkji
Normal  (normocellular) 

 nmlkji
Increased  (hypercellular) 

 nmlkji
Unknown  

 

 
28  Fibrosis

    
 nmlkji

Present  
 nmlkji

Absent  
 nmlkji

Unknown  

 

 
29  Were tests for molecular markers performed (e.g. PCR)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
30  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
31  ASXL1

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
32  JAK2

    (For MPN only)  

 nmlkji
Positive  

 nmlkji
Negative  

 nmlkji
Not Done  

 

 
33  ETV6

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
34  EZH2

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
35  P53

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
36  RUNX1

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
37  Other molecular marker

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
38  Specify other molecular marker:    

 

 
39  Was documentation submitted to the CIBMTR?

    
 nmlkji

yes  
 nmlkji

no  

  Other Molecular Marker (1) Questions: 37 - 38 

  Pre-HCT Therapy Questions: 40 - 122

Form 2014 R3.0: Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Pre-HCT Data  
Center:  CRID: 

           CIBMTR Form 2014 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 3 / 12



 

 
40  Was therapy given?

    
 nmlkji

yes  
 nmlkji

no  

Specify laboratory findings immediately prior to this line of therapy: 

 

 
41  WBC

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
42     

 

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 

 
43  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
44  Hemoglobin

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
45     

 

 

 nmlkji
g/dL  

 nmlkji
g/L  

 nmlkji
mmol/L  

 

 
46  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
47  Was RBC transfused < 30 days before date of test?

    
 nmlkji

yes  
 nmlkji

no  

 

 
48  Platelets

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
49     

 

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 

 
50  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
51  Were platelets transfused < 7 days before date of test?

    
 nmlkji

yes  
 nmlkji

no  

 

 
52  Neutrophils

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
53     % 

 

 
54  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
55  Blasts in bone marrow

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
56     % 

 

 
57  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
58  Were cytogenetics tested (conventional or FISH)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
59  Date sample collected: __ __ __ __ - __ __- __ __  

  Line of Therapy (1) Questions: 41 - 122 

Form 2014 R3.0: Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Pre-HCT Data  
Center:  CRID: 

           CIBMTR Form 2014 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 4 / 12



 

 
60  Results of tests

    
 nmlkji

Abnormalities identified  

 nmlkji
No evaluable metaphases  

 nmlkji
No abnormalities  

Specify abnormalities identified prior to this line of therapy: 

 

 
61  Specify number of distinct cytogenetic abnormalities

    
 nmlkji

One (1)  

 nmlkji
Two (2)  

 nmlkji
Three (3)  

 nmlkji
Four or more (4 or more)  

Monosomy 

 

 
62  –5

    
 nmlkji

yes  
 nmlkji

no  

 

 
63  -7

    
 nmlkji

yes  
 nmlkji

no  

 

 
64  –13

    
 nmlkji

yes  
 nmlkji

no  

 

 
65  –20

    
 nmlkji

yes  
 nmlkji

no  

 

 
66  –Y

    
 nmlkji

yes  
 nmlkji

no  

Trisomy 

 

 
67  +8

    
 nmlkji

yes  
 nmlkji

no  

 

 
68  +19

    
 nmlkji

yes  
 nmlkji

no  

Translocation 

 

 
69  t(1;3)

    
 nmlkji

yes  
 nmlkji

no  

 

 
70  t(2;11)

    
 nmlkji

yes  
 nmlkji

no  

 

 
71  t(3;3)

    
 nmlkji

yes  
 nmlkji

no  

 

 
72  t(3;21)

    
 nmlkji

yes  
 nmlkji

no  

Form 2014 R3.0: Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Pre-HCT Data  
Center:  CRID: 

           CIBMTR Form 2014 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 5 / 12



 

 
73  t(6;9)

    
 nmlkji

yes  
 nmlkji

no  

 

 
74  t(11;16)

    
 nmlkji

yes  
 nmlkji

no  

Deletion 

 

 
75  del(3q) / 3q–

    
 nmlkji

yes  
 nmlkji

no  

 

 
76  del(5q) / 5q-

    
 nmlkji

yes  
 nmlkji

no  

 

 
77  del(7q) / 7q–

    
 nmlkji

yes  
 nmlkji

no  

 

 
78  del(9q) / 9q–

    
 nmlkji

yes  
 nmlkji

no  

 

 
79  del(11q) / 11q–

    
 nmlkji

yes  
 nmlkji

no  

 

 
80  del(12p) / 12p–

    
 nmlkji

yes  
 nmlkji

no  

 

 
81  del(13q) / 13q-

    
 nmlkji

yes  
 nmlkji

no  

 

 
82  del(20q) / 20q–

    
 nmlkji

yes  
 nmlkji

no  

Inversion 

 

 
83  inv(3)

    
 nmlkji

yes  
 nmlkji

no  

Other 

 

 
84  i17q

    
 nmlkji

yes  
 nmlkji

no  

 

 
85  Other abnormality

    
 nmlkji

yes  
 nmlkji

no  

 

 
86  Specify other abnormality:    

Line of Therapy 

 

 
87  Systemic therapy

    
 nmlkji

yes  
 nmlkji

no  

 

 
88  Date therapy started

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
89  Date started: __ __ __ __ - __ __- __ __  

Form 2014 R3.0: Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Pre-HCT Data  
Center:  CRID: 

           CIBMTR Form 2014 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 6 / 12



 

 
90  Date therapy stopped

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
91  Date stopped: __ __ __ __ - __ __- __ __  

 

 
92  Androgen

    
 nmlkji

yes  
 nmlkji

no  

 

 
93  Antithymocyte globulin (ATG)

    
 nmlkji

yes  
 nmlkji

no  

 

 
94  Azacytidine (Vidaza)

    
 nmlkji

yes  
 nmlkji

no  

 

 
95  Bendamustine

    
 nmlkji

yes  
 nmlkji

no  

 

 
96  Corticosteroids

    
 nmlkji

yes  
 nmlkji

no  

 

 
97  Cytarabine (Ara-C)

    
 nmlkji

yes  
 nmlkji

no  

 

 
98  Decitabine (Dacogen)

    
 nmlkji

yes  
 nmlkji

no  

 

 
99  Deferiprone (Ferriprox)

    
 nmlkji

yes  
 nmlkji

no  

 

 
100  Deferasirox (Exjade)

    
 nmlkji

yes  
 nmlkji

no  

 

 
101  Deferoxamine (Desferal)

    
 nmlkji

yes  
 nmlkji

no  

 

 
102  Erythropoietin (EPO)

    (any formulation)  

 nmlkji
yes  

 nmlkji
no  

 

 
103  G-CSF

    (any formulation)  

 nmlkji
yes  

 nmlkji
no  

 

 
104  GM-CSF

    
 nmlkji

yes  
 nmlkji

no  

 

 
105  Hydroxyurea (Droxia, Hydrea)

    
 nmlkji

yes  
 nmlkji

no  

 

 
106  Idarubicin (Idamycin)

    
 nmlkji

yes  
 nmlkji

no  

Form 2014 R3.0: Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Pre-HCT Data  
Center:  CRID: 

           CIBMTR Form 2014 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 7 / 12



 

 
107  Lenalidomide (Revlimid)

    
 nmlkji

yes  
 nmlkji

no  

 

 
108  Ruxolitinib (Jakafi)

    
 nmlkji

yes  
 nmlkji

no  

 

 
109  Thalidomide (Thalomid)

    
 nmlkji

yes  
 nmlkji

no  

 

 
110  Tyrosine kinase inhibitor

    (e.g. imatinib mesylate)  

 nmlkji
yes  

 nmlkji
no  

 

 
111  Other systemic therapy

    
 nmlkji

yes  
 nmlkji

no  

 

 
112  Specify other systemic therapy:    

 

 
113  Other therapy

    
 nmlkji

yes  
 nmlkji

no  

 

 
114  Splenic radiation

    
 nmlkji

yes  
 nmlkji

no  

 

 
115  Splenectomy

    
 nmlkji

yes  
 nmlkji

no  

 

 
116  Other therapy

    
 nmlkji

yes  
 nmlkji

no  

 

 
117  Specify other therapy:    

 

 
118  Best response to line of therapy

    
 nmlkji

Complete 

remission (CR)  

- requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: < 5% myeloblasts with normal maturation of all cell lines * 
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000 / mm3  without myeloid 
growth factor support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts  

 nmlkji
Hematologic 

improvement 

(HI)  

- requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was 
measured to determine HI response: * HI-E- hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, 
reduction in RBC units transfused in 8 weeks by ≥ 4 units compared to the pre-treatment transfusion number in the previous 8 weeks * HI-P- 
for pre-treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, 
platelet absolute increase of ≥ 20 x 109 /L and ≥100% from  pre-treatment level * HI-N- neutrophil count increase of ≥ 100% from pre-
treatment level and an absolute increase of ≥ 500 / mm3  

 nmlkji
No response (NR) / stable disease (SD)  - does not meet the criteria for at least HI, but no evidence of disease progression 

 nmlkji
Progression from hematologic 

improvement (Prog from HI)  

- requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing 

chemotherapy, etc.): * ≥ 50% reduction from maximum response levels in granulocytes or platelets *  reduction in 
hemoglobin by ≥ 1.5 g/dL * transfusion dependence  

 nmlkji
Relapse from complete 

remission (Rel from CR)  

- requires at least one of the following: * return to pre-treatment bone marrow blast percentage * decrease of ≥ 50% from 
maximum response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior 
to therapy  

 nmlkji
Progression to AML (AML)  - ≥ 20% blasts in the bone marrow 

 nmlkji
Unknown  

 nmlkji
Not assessed  

Form 2014 R3.0: Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Pre-HCT Data  
Center:  CRID: 

           CIBMTR Form 2014 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 8 / 12



 

 
119  Specify the cell line examined to determine HI status

    
 nmlkji

HI-

E  

- hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks 
by ≥ 4 units compared to the pre-treatment transfusion number in 8 weeks.  

 nmlkji
HI-

P  

- for pre-treatment platelet count of > 20x 109 /L, platelet absolute increase of ≥ 30 x 109 /L; for pre-treatment platelet count of < 20 x 109 /L, platelet 
absolute increase of ≥ 20 x 109 /L and ≥ 100% from pre-treatment level  

 nmlkji
HI-N  - neutrophil count increase of ≥ 100% from pre-treatment level and an absolute increase of ≥ 500 / mm3 

 

 
120  Date assessed: __ __ __ __ - __ __- __ __  

 

 
121  Did disease relapse/progress following this line of therapy?

    
 nmlkji

yes  
 nmlkji

no  

 

 
122  Date of relapse/progression: __ __ __ __ - __ __- __ __  

 

 
123  Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

    
 nmlkji

yes  
 nmlkji

no  

 

 
124  Was a subsequent complete remission achieved?

    
 nmlkji

yes  
 nmlkji

no  

 

 
125  Specify the date of the most recent transformation: __ __ __ __ - __ __- __ __  

 

 
126  Specify the MDS / MPN subtype after transformation

    
 nmlkji

Refractory cytopenia with unilineage dysplasia (RCUD) (includes refractory anemia (RA)) (51)  

 nmlkji
Refractory anemia with ringed sideroblasts (RARS) (55)  

 nmlkji
Refractory anemia with excess blasts-1 (RAEB-1) (61)  

 nmlkji
Refractory anemia with excess blasts-2 (RAEB-2) (62)  

 nmlkji
Refractory cytopenia with multilineage dysplasia (RCMD) (64)  

 nmlkji
Childhood myelodysplastic syndrome (Refractory cytopenia of childhood (RCC)) (68)  

 nmlkji
Myelodysplastic syndrome with isolated del(5q) (5q– syndrome) (66)  

 nmlkji
Myelodysplastic syndrome (MDS), unclassifiable (50)  

 nmlkji
Chronic neutrophilic leukemia (165)  

 nmlkji
Chronic eosinophilic leukemia, NOS (166)  

 nmlkji
Essential thrombocythemia (includes primary thrombocytosis, idiopathic thrombocytosis, hemorrhagic thrombocythemia) (58)  

 nmlkji
Polycythemia vera (PCV) (57)  

 nmlkji
Primary myelofibrosis (includes chronic idiopathic myelofibrosis (CIMF), angiogenic myeloid metaplasia (AMM), myelofibrosis/sclerosis with myeloid 

metaplasia (MMM), idiopathic myelofibrosis) (167)  

 nmlkji
Myeloproliferative neoplasm (MPN), unclassifiable (60)  

 nmlkji
Chronic myelomonocytic leukemia (CMMoL) (54)  

 nmlkji
Myelodysplastic / myeloproliferative neoplasm, unclassifiable (69)  

 nmlkji
Transformed to AML (70)  - Also complete CIBMTR form 2010 

  Transformation Questions: 123 - 126

Form 2014 R3.0: Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Pre-HCT Data  
Center:  CRID: 

           CIBMTR Form 2014 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 9 / 12



 

 
127  Monocytes

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
128     % 

 

 
129  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
130  Blasts in blood

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
131     % 

 

 
132  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
133  Was a bone marrow examination performed?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
134  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
135  Cellularity

    
 nmlkji

Decreased  (hypocellular) 

 nmlkji
Normal  (normocellular) 

 nmlkji
Increased  (hypercellular) 

 nmlkji
Unknown  

 

 
136  Fibrosis

    
 nmlkji

Present  
 nmlkji

Absent  
 nmlkji

Unknown  

 

 
137  Were tests for molecular markers performed (e.g. PCR)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
138  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
139  ASXL1

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
140  JAK2

    (For MPN only)  

 nmlkji
Positive  

 nmlkji
Negative  

 nmlkji
Not Done  

 

 
141  ETV6

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
142  EZH2

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
143  P53

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
144  RUNX1

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

  Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen(Conditioning) Questions: 127 - 153

  Other Molecular Marker (1) Questions: 145 - 146 

Form 2014 R3.0: Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Pre-HCT Data  
Center:  CRID: 

           CIBMTR Form 2014 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 10 / 12



 

 
145  Other molecular marker

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
146  Specify other molecular marker:    

 

 
147  Was flow cytometry performed?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Specify tissue and results: 

 

 
148  Blood

    
 nmlkji

yes  
 nmlkji

no  

 

 
149  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
150  Was disease detected?

    
 nmlkji

yes  
 nmlkji

no  

 

 
151  Bone marrow

    
 nmlkji

yes  
 nmlkji

no  

 

 
152  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
153  Was disease detected?

    
 nmlkji

yes  
 nmlkji

no  

 

 
154  Were systemic symptoms (B symptoms) present?

    (unexplained fever > 38 C; or night sweats; unexplained weight loss > 10% body weight in six months before last evaluation prior to the start of the preparative regimen) 

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 

 
155  Did the recipient have splenomegaly (spleen palpable > 3 cm below left costal margin)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
156  Did the recipient have hepatomegaly (liver edge palpable > 3 cm below right costal margin)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
157  What was the disease status?

    
 nmlkji

Complete 

remission (CR)  

- requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: < 5% myeloblasts with normal maturation of all cell lines * 
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000 / mm3 without myeloid growth factor 
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts  

 nmlkji
Hematologic 

improvement 

(HI)  

- requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to 
determine HI response: * HI-E- hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC 
units transfused in 8 weeks by ≥ 4 units compared to the pre-treatment transfusion number in the previous 8 weeks * HI-P- for pre-treatment platelet 
count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L 
and ≥ 100% from  pre-treatment level * HI-N- neutrophil count increase of ≥ 100% from pre-treatment level and an absolute increase of ≥ 500 / mm3  

 nmlkji
No response (NR) / stable disease (SD)  - does not meet the criteria for at least HI, but no evidence of disease progression 

 nmlkji
Progression from hematologic 

improvement (Prog from HI)  

- requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): 

* ≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL * transfusion 
dependence  

 nmlkji
Relapse from complete 

remission (Rel from CR)  

- requires at least one of the following: * return to pre-treatment bone marrow blast percentage * decrease of ≥ 50% from maximum 
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy  

 nmlkji
Not assessed  

  Disease Assessment at the Last Evaluation Prior to the Preparative Regimen (Conditioning) Questions: 154 - 161

Form 2014 R3.0: Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Pre-HCT Data  
Center:  CRID: 

           CIBMTR Form 2014 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 11 / 12



 

 
158  Specify the cell line examined to determine HI status

    
 nmlkji

HI-

E  

- hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4 units 
compared to the pre-treatment transfusion number in 8 weeks  

 nmlkji
HI-

P  

- for pre-treatment platelet count of > 20 x 109 /L, platelet absolute increase of ≥ 30 x 109 /L; for pre-treatment platelet count of < 20 x 109 /L, platelet absolute 
increase of ≥ 20x 109 /L and ≥ 100% from pre-treatment level  

 nmlkji
HI-N  - neutrophil count increase of ≥ 100% from pre-treatment level and an absolute increase of ≥ 500 / mm3  

 

 
159  Date of progression: __ __ __ __ - __ __- __ __  

 

 
160  Date of relapse: __ __ __ __ - __ __- __ __  

 

 
161  Date assessed: __ __ __ __ - __ __- __ __  

 

 
First Name:    

 

 
Last Name:    

 

 
E-mail address:    

 

 
Date: __ __ __ __ - __ __- __ __  

Form 2014 R3.0: Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Pre-HCT Data  
Center:  CRID: 

           CIBMTR Form 2014 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 12 / 12